Promomed has launched the first-in-class drug Amberwin® Pulmo with a unique mechanism of action and high efficacy in improving lung health in a wide range of diseases. It is a bioregulator from the class of short peptides, created on the company's own technology platform. Active ingredient of the drug is a synthetic peptide of six amino acids combined with a...

Biopharmaceutical company Promomed and the Vietnamese pharmaceutical corporation Vinafarm signed a memorandum of understanding. Document defines the terms of cooperation in such areas as the commercialization of medicines, the development of production technologies, research and synthesis of new molecules. Cooperation with Vinafarm will allow Promomed to exp...

Promomed's net profit under IFRS for 6 months of 2025 amounted to ₽1.42 billion, a multiple increase from ₽0.005 billion in the previous year. Revenue increased by 81.9% to ₽12.97 billion from ₽7.13 billion a year earlier.

Promomed's revenue for 6 months of 2025 amounted to ₽13 billion, an increase of 82% compared to last year. Share of revenue from the sale of innovative products increased by 3 percentage points, to 60%. In the endocrinology segment, revenue increased 2.2 times to ₽4.8 billion. In the oncology segment, revenue increased 2.9 times and reached ₽4.7 billion.